Effect of Granulocyte Colony-Stimulating Factor after Intensive Induction Therapy in Relapsed or Refractory Acute Leukemia (Q67669614)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1697646%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

title

Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1697646%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

Effect of Granulocyte Colony-Stimulating Factor after Intensive Induction Therapy in Relapsed or Refractory Acute Leukemia (English)

1 reference

https://api.crossref.org/works/10.1056/NEJM199009273231304

1 November 2022

1 reference

Ohno R

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1697646%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

Tomonaga M

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1697646%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

Kobayashi T

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1697646%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

Kanamaru A

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1697646%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

Shirakawa S

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1697646%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

Masaoka T

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1697646%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

Omine M

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1697646%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

Oh H

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1697646%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

Nomura T

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1697646%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

Sakai Y

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1697646%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1697646

1 November 2022

publication date

1 September 1990

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1697646%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

27 September 1990

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1697646

full work available at URL

1 November 2022

http://www.nejm.org/doi/pdf/10.1056/NEJM199009273231304

1 reference

https://api.crossref.org/works/10.1056/NEJM199009273231304

The New England Journal of Medicine

1 November 2022

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1697646%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

volume

323

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1697646%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

issue

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1697646%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

page(s)

871-877

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1697646%20AND%20SRC:MED&resulttype=core&format=json

Nihon Ketsueki Gakkai zasshi

16 September 2019

cites work

2

52

287

Ohno

1989

1 reference

https://api.crossref.org/works/10.1056/NEJM199009273231304

Hematopoietic growth factors. Biology and clinical applications

1 November 2022

4

1 reference

https://api.crossref.org/works/10.1056/NEJM199009273231304

Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer

1 November 2022

6

1 reference

https://api.crossref.org/works/10.1056/NEJM199009273231304

Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression

1 November 2022

7

1 reference

https://api.crossref.org/works/10.1056/NEJM199009273231304

Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium

1 November 2022

8

1 reference

https://api.crossref.org/works/10.1056/NEJM199009273231304

Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Hematopoietic Reconstitution after High-Dose Chemotherapy and Autologous Bone Marrow Transplantation

1 November 2022

10

1 reference

https://api.crossref.org/works/10.1056/NEJM199009273231304

Acceleration of neutrophilic granulocyte recovery after bone-marrow transplantation by administration of recombinant human granulocyte colony-stimulating factor.

1 November 2022

11

1 reference

https://api.crossref.org/works/10.1056/NEJM199009273231304

Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation

1 November 2022

15

1 reference

https://api.crossref.org/works/10.1056/NEJM199009273231304

Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells

1 November 2022

18

1 reference

https://api.crossref.org/works/10.1056/NEJM199009273231304

Response of leukemic cells to the sequential combination of gm‐csf and g‐csf

1 November 2022

23

1 reference

https://api.crossref.org/works/10.1056/NEJM199009273231304

Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length.

1 November 2022

26

1 reference

https://api.crossref.org/works/10.1056/NEJM199009273231304

Response to salvage therapy and survival after relapse in acute myelogenous leukemia.

1 November 2022

27

1 reference

https://api.crossref.org/works/10.1056/NEJM199009273231304

Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes

1 November 2022

29

1 reference

https://api.crossref.org/works/10.1056/NEJM199009273231304

Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor: a preliminary report

1 November 2022

31

1 reference

https://api.crossref.org/works/10.1056/NEJM199009273231304

Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial

1 November 2022

32

1 reference

https://api.crossref.org/works/10.1056/NEJM199009273231304

1 November 2022

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1697646%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

1 reference